Oncology Institute Q3 revenue jumps, partly on organic growth in Florida, Oregon
I'm PortAI, I can summarize articles.
Oncology Institute's Q3 revenue increased by 36.7% year-over-year, driven by organic growth in Florida and Oregon. The net loss widened slightly to $16.5 million. The company updated its full-year revenue guidance to $495-$505 million and revised its Adjusted EBITDA guidance. Fee-for-service revenue grew 13%, and pharmacy records contributed significantly. Analysts rate the shares as "buy," with a median price target of $7.00, 51% above the current price.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments